683 Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

683 Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-60,000	Closed	-$1.26M	–	171
2023 Q2	$1.26M	Sell	60,000 -330,000	-85%	-$6.87M	0.09%	104
2023 Q1	$8.24M	Sell	390,000 -180,000	-32%	-$4.48M	0.61%	49
2022 Q4	$14.5M	Sell	570,000 -560,000	-50%	-$13.1M	1.23%	26
2022 Q3	$27.2M	Sell	1,130,000 -451,653	-29%	-$10.1M	2.1%	11
2022 Q2	$30.4M	Hold	1,581,653	–	–	2.15%	10
2022 Q1	$27.5M	Buy	1,581,653 +186,161	+13%	+$3.13M	1.47%	14
2021 Q4	$30.5M	Buy	1,395,492 +259,592	+23%	+$4.8M	1.12%	17
2021 Q3	$21.7M	Buy	1,135,900 +50,000	+5%	+$833K	0.85%	32
2021 Q2	$18.6M	Buy	1,085,900 +250,900	+30%	+$4.6M	0.64%	41
2021 Q1	$18.7M	Sell	835,000 -153,406	-16%	-$3.47M	0.99%	30
2020 Q4	$22M	Buy	988,406 +160,035	+19%	+$3.32M	1.04%	22
2020 Q3	$12.2M	Sell	828,371 -188,000	-18%	-$2.87M	0.9%	26
2020 Q2	$15.1M	Buy	1,016,371 +83,333	+9%	+$1.27M	1.21%	24
2020 Q1	$10.2M	Buy	933,038 +8,038	+0.9%	+$75.4K	1.2%	24
2019 Q4	$8.12M	Sell	925,000 -246,648	-21%	-$1.81M	0.93%	28
2019 Q3	$8.75M	Sell	1,171,648 -444,307	-27%	-$4.05M	0.97%	30
2019 Q2	$15M	Buy	1,615,955 +17,598	+1%	+$128K	1.37%	21
2019 Q1	$8.39M	Buy	1,598,357 +255,518	+19%	+$1.46M	0.76%	36
2018 Q4	$5.98M	Buy	1,342,839 +821,839	+158%	+$4.51M	0.36%	52
2018 Q3	$4.21M	Buy	521,000 +146,000	+39%	+$1.04M	0.27%	62
2018 Q2	$2.63M	Buy	375,000 +91,770	+32%	+$900K	0.18%	72
2018 Q1	$4.03M	Buy	+283,230	New	+$3.01M	0.36%	60

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

683 Capital Management's SNDX Position: Q3 2023 in Review

683 Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2023, closing a stake of 60,000 shares — an estimated $1.26M sold.

683 Capital Management first reported a position in SNDX in Q1 2018 and held it in 22 quarters. The position peaked at $30.5M in Q4 2021. 175 funds tracked by Wall St. Rank hold SNDX as of Q3 2023.

683 Capital Management reported no remaining Syndax Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
683 Capital Management sold 60,000 Syndax Pharmaceuticals shares in Q3 2023, an estimated $1.26M.
683 Capital Management first reported a position in Syndax Pharmaceuticals in Q1 2018 and held it in 22 quarters.
683 Capital Management's Syndax Pharmaceuticals position peaked at $30.5M in Q4 2021.
175 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2023.

Based on 683 Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.